---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-045371"
form_type: "8-K"
ticker: "ZVSA"
cik: "0001859007"
company_name: "ZyVersa Therapeutics, Inc."
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:37:32.128493+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ZyVersa Q3 net loss $2.4M, cash only $0.1M; Phase 2a trial expected Q1 2025

## Summary
- Net loss improved 17.3% to $2.4M from $2.9M YoY; R&D and G&A expenses decreased.
- Cash at Sept 30, 2024: $0.1M; company will need additional financing on a month-to-month basis.
- Phase 2a trial for VAR 200 in diabetic kidney disease expected to begin Q1 2025 with data mid-2025.
- IC 100 IND submission planned for Q2 2025; Phase 1 trial in overweight subjects planned Q2/Q3 2025.
- Raised ~$3.9M from Q3 2024 to present; formed new Obesity, Metabolic & Inflammatory Disease SAB.

## SEC filing metadata
- accession: 0001493152-24-045371
- form_type: 8-K
- ticker: ZVSA
- cik: 0001859007
- company_name: ZyVersa Therapeutics, Inc.
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1859007/000149315224045371/0001493152-24-045371-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1859007/000149315224045371/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-045371
- JSON: https://secwatch.observer/filing/0001493152-24-045371.json
- Plain text: https://secwatch.observer/filing/0001493152-24-045371.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.